![tripeptide 29 tripeptide 29 is a small, naturally occurring amino acid peptide, one of the primary building blocks for collagen protein.(1) collagen is a major component of the extracellular matrix, the network of proteins and fibers comprising connective tissues. it is considered responsible for providing structure and support to cellular complexes. researchers suggest tripeptide 29 may have the potential to stimulate collagen synthesis and promote the formation of collagen fibers. in addition to its possible role in collagen synthesis, tripeptide 29 may have other biological functions. for example, research studies have hypothesized its potential as an antioxidant, which might help protect cells from oxidative stress and damage. it may also exhibit anti inflammatory, anti fibrotic, and anti melanogenic characteristics. chemical makeup molecular formula: c12h19n3o5 molecular weight: 285.3 g/mol other known titles: glycylprolylhydroxyproline research and clinical studies tripeptide 29 and collagen integrity tripeptide 29 may be a major contributor to the stability of type 1 collagen molecules. studies suggest that the oh group of hyp in tripeptide 29 may contribute to the formation of favorable interatomic interactions.(2) the researchers propose that tripeptide 29 as a monomer may enhance the stability of collagen and collagen microfibrils. studies also suggest that the presence of tripeptide 29 as a part of the sequence in collagen may significantly reduce uv related damage and lower the degradation rate when exposed to intensive radiation.(3) a study conducted on dermal fibroblasts reported that hydrolyzed type 1 collagen tripeptides exhibited promising potential in reducing oxidative stress and damage.(4) as previously noted, tripeptide 29 appears to be the primary tripeptide that forms when hydrolyzing type 1 collagen. the hydrolysate showed potential in reducing the build up of advanced glycation end products (ages), reportedly preventing the production of denatured collagen and lowering levels of reactive oxygen species. the glycation process refers to sugar molecules bonding with proteins, potentially speeding up skin cell aging by altering its mechanical properties and stability. ultimately, the scientists suggested that tripeptide 29 “might improve [cell aging] phenotypes via the inhibition of glycation and oxidative stress, leading to a delay in cellular aging.” from an in vitro perspective, the study explored the mechanisms underpinning the observed action. it was suggested that tripeptide 29 may reduce the production of ages and denatured collagen while inhibiting the activity of matrix metalloproteinases (mmps) and enhancing collagen 1 levels in dermal fibroblasts. these results suggest that tripeptide 29 may mitigate cell aging by preserving collagen integrity and inhibiting processes that degrade the skin matrix. furthermore, it is indicated that tripeptide 29 might be linked to its smaller peptide size, which is believed to support its skin penetration and bioavailability. tripeptide 29 and glucose control according to researchers, tripeptide 29 may act as a peptidic inhibitor of dipeptidyl peptidase iv (dpp iv) due to its potential to inhibit the hydrolysis of the pro hyp bond.(5) it was considered a moderately competitive inhibitor. the scientists reported that “gly pro hyp in the collagen hydrolysates is suggested to be mainly responsible for the dpp iv inhibition in vitro,” inferring that tripeptide 29 may contribute to the overall inhibitory action of collagen peptides on dpp iv. interestingly, tripeptide 29 was reportedly not hydrolyzed by dpp iv, indicating resistance to this specific enzyme. this observation might point to the peptide's stability and efficacy in the presence of this enzyme. dipeptidyl peptidase iv (dpp iv) is a serine peptidase involved in several biological processes.(6) the enzyme is expressed on the surface of various cell types, including immune cells, epithelial cells, and endothelial cells. it is also apparently found in circulation in the liver, kidney, and intestine tissues. dpp iv cleaves peptide bonds at the n terminus of dipeptides, tripeptides, and smaller peptides, but not larger peptides or proteins. this specificity means it may act on various substrates, including hormones, neuropeptides, and chemokines. some of the substrates of dpp iv include glucagon like peptide 1 (glp 1), glucose dependent insulinotropic polypeptide (gip), and peptide yy (pyy), all of which are suggested to be involved in the regulation of glucose homeostasis and energy metabolism.(7) the cleavage of glp 1 and gip by dpp iv may result in rapid inactivation and clearance from circulation. inhibiting dpp iv may upregulate the levels of glp 1 and gip, which may lead to an increase in insulin secretion, reduction in glucagon levels, lower blood glucose, and decreased appetite.(8) tripeptide 29 and platelet aggregation collagen related peptides that contain a glycine proline hydroxyproline repeat motif are considered to be cross linked through cysteine residues, which may stimulate platelet aggregation and secretion through glycoprotein vi (gpvi) receptors. gpvi is a platelet receptor that scientists believe to be crucial in blood clotting or hemostasis. it is a transmembrane glycoprotein that appears to be primarily expressed on the surface of platelets, which are blood cells involved in blood clotting. gpvi is a member of the immunoglobulin (ig) superfamily of proteins, comprised of two subunits called alpha and beta. the alpha subunit is considered to contain the collagen binding site, while the beta subunit is deemed responsible for signaling within the platelet. when the gpvi receptor binds to collagen, it may trigger a series of events that lead to the activation of platelets and the formation of a blood clot. studies suggest that the non cross linked form of glycine proline hydroxyproline, or tripeptide 29, may induce tyrosine phosphorylation of the tyrosine kinase syk and phospholipase c gamma2 (plcgamma2) in platelets.(9) this may ultimately stimulate platelet aggregation to stop or prevent bleeding. overall, the researchers report that tripeptide 29, “present as a repeat motif, is sufficient to activate the platelet collagen receptor gpvi,” and may stimulate the formation of thrombi to prevent excessive bleeding. tripeptide 29 peptide is available for research and laboratory purposes only. please review and adhere to our terms and conditions before ordering. references: wiśniewski, k., artemowicz, b., lutostańska, a., maćkowiak, j., & koziołkiewicz, w. (1994). central activity of peptide gly pro hyp the main component of collagen degradation products mixture. acta neurobiologiae experimentalis, 54(1), 33–38. némethy, g., & scheraga, h. a. (1986). stabilization of collagen fibrils by hydroxyproline. biochemistry, 25(11), 3184–3188. target=" blank" rel="noopener"https://doi.org/10.1021/bi00359a016 jariashvili, k., madhan, b., brodsky, b., kuchava, a., namicheishvili, l., & metreveli, n. (2012). uv damage of collagen: insights from model collagen peptides. biopolymers, 97(3), 189–198. https://doi.org/10.1002/bip.21725 lee, y. i., lee, s. g., jung, i., suk, j., lee, m. h., kim, d. u., & lee, j. h. (2022). effect of a collagen tripeptide on antiaging and inhibition of glycation of the skin: a pilot study. international journal of molecular sciences, 23(3), 1101. https://doi.org/10.3390/ijms23031101 hatanaka, t., kawakami, k., & uraji, m. (2014). inhibitory effect of collagen derived tripeptides on dipeptidylpeptidase iv activity. journal of enzyme inhibition and medicinal chemistry, 29(6), 823–828. https://doi.org/10.3109/14756366.2013.858143 trzaskalski, n. a., fadzeyeva, e., & mulvihill, e. e. (2020). dipeptidyl peptidase 4 at the interface between inflammation and metabolism. clinical medicine insights. endocrinology and diabetes, 13, 1179551420912972. https://doi.org/10.1177/1179551420912972 kieffer, t. j., mcintosh, c. h., & pederson, r. a. (1995). degradation of glucose dependent insulinotropic polypeptide and truncated glucagon like peptide 1 in vitro and in vivo by dipeptidyl peptidase iv. endocrinology, 136(8), 3585–3596. https://doi.org/10.1210/endo.136.8.7628397 kasina, s. v. s. k., & baradhi, k. m. (2022). dipeptidyl peptidase iv (dpp iv) inhibitors. in statpearls. statpearls publishing. asselin, j., knight, c. g., farndale, r. w., barnes, m. j., & watson, s. p. (1999). monomeric (glycine proline hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein vi. the biochemical journal, 339 ( pt 2)(pt 2), 413–418. dr. marinov dr. marinov (md, ph.d.) is a researcher and chief assistant professor in preventative medicine & public health. prior to his professorship, dr. marinov practiced preventative, evidence based medicine with an emphasis on nutrition and dietetics. he is widely published in international peer reviewed scientific journals and specializes in peptide therapy research.](https://peplabshop.eu/wp-content/uploads/2026/03/Triptorelin-2MG-265x265-1.webp "tripeptide 29 tripeptide 29 is a small, naturally occurring amino acid peptide, one of the primary building blocks for collagen protein.(1) collagen is a major component of the extracellular matrix, the network of proteins and fibers comprising connective tissues. it is considered responsible for providing structure and support to cellular complexes. researchers suggest tripeptide 29 may have the potential to stimulate collagen synthesis and promote the formation of collagen fibers. in addition to its possible role in collagen synthesis, tripeptide 29 may have other biological functions. for example, research studies have hypothesized its potential as an antioxidant, which might help protect cells from oxidative stress and damage. it may also exhibit anti inflammatory, anti fibrotic, and anti melanogenic characteristics. chemical makeup molecular formula: c12h19n3o5 molecular weight: 285.3 g/mol other known titles: glycylprolylhydroxyproline research and clinical studies tripeptide 29 and collagen integrity tripeptide 29 may be a major contributor to the stability of type 1 collagen molecules. studies suggest that the oh group of hyp in tripeptide 29 may contribute to the formation of favorable interatomic interactions.(2) the researchers propose that tripeptide 29 as a monomer may enhance the stability of collagen and collagen microfibrils. studies also suggest that the presence of tripeptide 29 as a part of the sequence in collagen may significantly reduce uv related damage and lower the degradation rate when exposed to intensive radiation.(3) a study conducted on dermal fibroblasts reported that hydrolyzed type 1 collagen tripeptides exhibited promising potential in reducing oxidative stress and damage.(4) as previously noted, tripeptide 29 appears to be the primary tripeptide that forms when hydrolyzing type 1 collagen. the hydrolysate showed potential in reducing the build up of advanced glycation end products (ages), reportedly preventing the production of denatured collagen and lowering levels of reactive oxygen species. the glycation process refers to sugar molecules bonding with proteins, potentially speeding up skin cell aging by altering its mechanical properties and stability. ultimately, the scientists suggested that tripeptide 29 “might improve [cell aging] phenotypes via the inhibition of glycation and oxidative stress, leading to a delay in cellular aging.” from an in vitro perspective, the study explored the mechanisms underpinning the observed action. it was suggested that tripeptide 29 may reduce the production of ages and denatured collagen while inhibiting the activity of matrix metalloproteinases (mmps) and enhancing collagen 1 levels in dermal fibroblasts. these results suggest that tripeptide 29 may mitigate cell aging by preserving collagen integrity and inhibiting processes that degrade the skin matrix. furthermore, it is indicated that tripeptide 29 might be linked to its smaller peptide size, which is believed to support its skin penetration and bioavailability. tripeptide 29 and glucose control according to researchers, tripeptide 29 may act as a peptidic inhibitor of dipeptidyl peptidase iv (dpp iv) due to its potential to inhibit the hydrolysis of the pro hyp bond.(5) it was considered a moderately competitive inhibitor. the scientists reported that “gly pro hyp in the collagen hydrolysates is suggested to be mainly responsible for the dpp iv inhibition in vitro,” inferring that tripeptide 29 may contribute to the overall inhibitory action of collagen peptides on dpp iv. interestingly, tripeptide 29 was reportedly not hydrolyzed by dpp iv, indicating resistance to this specific enzyme. this observation might point to the peptide's stability and efficacy in the presence of this enzyme. dipeptidyl peptidase iv (dpp iv) is a serine peptidase involved in several biological processes.(6) the enzyme is expressed on the surface of various cell types, including immune cells, epithelial cells, and endothelial cells. it is also apparently found in circulation in the liver, kidney, and intestine tissues. dpp iv cleaves peptide bonds at the n terminus of dipeptides, tripeptides, and smaller peptides, but not larger peptides or proteins. this specificity means it may act on various substrates, including hormones, neuropeptides, and chemokines. some of the substrates of dpp iv include glucagon like peptide 1 (glp 1), glucose dependent insulinotropic polypeptide (gip), and peptide yy (pyy), all of which are suggested to be involved in the regulation of glucose homeostasis and energy metabolism.(7) the cleavage of glp 1 and gip by dpp iv may result in rapid inactivation and clearance from circulation. inhibiting dpp iv may upregulate the levels of glp 1 and gip, which may lead to an increase in insulin secretion, reduction in glucagon levels, lower blood glucose, and decreased appetite.(8) tripeptide 29 and platelet aggregation collagen related peptides that contain a glycine proline hydroxyproline repeat motif are considered to be cross linked through cysteine residues, which may stimulate platelet aggregation and secretion through glycoprotein vi (gpvi) receptors. gpvi is a platelet receptor that scientists believe to be crucial in blood clotting or hemostasis. it is a transmembrane glycoprotein that appears to be primarily expressed on the surface of platelets, which are blood cells involved in blood clotting. gpvi is a member of the immunoglobulin (ig) superfamily of proteins, comprised of two subunits called alpha and beta. the alpha subunit is considered to contain the collagen binding site, while the beta subunit is deemed responsible for signaling within the platelet. when the gpvi receptor binds to collagen, it may trigger a series of events that lead to the activation of platelets and the formation of a blood clot. studies suggest that the non cross linked form of glycine proline hydroxyproline, or tripeptide 29, may induce tyrosine phosphorylation of the tyrosine kinase syk and phospholipase c gamma2 (plcgamma2) in platelets.(9) this may ultimately stimulate platelet aggregation to stop or prevent bleeding. overall, the researchers report that tripeptide 29, “present as a repeat motif, is sufficient to activate the platelet collagen receptor gpvi,” and may stimulate the formation of thrombi to prevent excessive bleeding. tripeptide 29 peptide is available for research and laboratory purposes only. please review and adhere to our terms and conditions before ordering. references: wiśniewski, k., artemowicz, b., lutostańska, a., maćkowiak, j., & koziołkiewicz, w. (1994). central activity of peptide gly pro hyp the main component of collagen degradation products mixture. acta neurobiologiae experimentalis, 54(1), 33–38. némethy, g., & scheraga, h. a. (1986). stabilization of collagen fibrils by hydroxyproline. biochemistry, 25(11), 3184–3188. target=\" blank\" rel=\"noopener\"https://doi.org/10.1021/bi00359a016 jariashvili, k., madhan, b., brodsky, b., kuchava, a., namicheishvili, l., & metreveli, n. (2012). uv damage of collagen: insights from model collagen peptides. biopolymers, 97(3), 189–198. https://doi.org/10.1002/bip.21725 lee, y. i., lee, s. g., jung, i., suk, j., lee, m. h., kim, d. u., & lee, j. h. (2022). effect of a collagen tripeptide on antiaging and inhibition of glycation of the skin: a pilot study. international journal of molecular sciences, 23(3), 1101. https://doi.org/10.3390/ijms23031101 hatanaka, t., kawakami, k., & uraji, m. (2014). inhibitory effect of collagen derived tripeptides on dipeptidylpeptidase iv activity. journal of enzyme inhibition and medicinal chemistry, 29(6), 823–828. https://doi.org/10.3109/14756366.2013.858143 trzaskalski, n. a., fadzeyeva, e., & mulvihill, e. e. (2020). dipeptidyl peptidase 4 at the interface between inflammation and metabolism. clinical medicine insights. endocrinology and diabetes, 13, 1179551420912972. https://doi.org/10.1177/1179551420912972 kieffer, t. j., mcintosh, c. h., & pederson, r. a. (1995). degradation of glucose dependent insulinotropic polypeptide and truncated glucagon like peptide 1 in vitro and in vivo by dipeptidyl peptidase iv. endocrinology, 136(8), 3585–3596. https://doi.org/10.1210/endo.136.8.7628397 kasina, s. v. s. k., & baradhi, k. m. (2022). dipeptidyl peptidase iv (dpp iv) inhibitors. in statpearls. statpearls publishing. asselin, j., knight, c. g., farndale, r. w., barnes, m. j., & watson, s. p. (1999). monomeric (glycine proline hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein vi. the biochemical journal, 339 ( pt 2)(pt 2), 413–418. dr. marinov dr. marinov (md, ph.d.) is a researcher and chief assistant professor in preventative medicine & public health. prior to his professorship, dr. marinov practiced preventative, evidence based medicine with an emphasis on nutrition and dietetics. he is widely published in international peer reviewed scientific journals and specializes in peptide therapy research.")
Triptorelin Peptide
Triptorelin is a synthetic peptide composed of ten amino acids, similar to gonadotropin-releasing hormones (GnRH).(1) GnRH, secreted by the hypothalamus, is considered by scientists to be responsible for the synthesis and secretion of the follicle-stimulating hormone (FSH) and luteinizing hormone (LH).(2) Triptorelin may act similarly on the pituitary gland to stimulate the synthesis and release of the LH and FSH hormones, both apparently vital for testosterone production in male species and estrogen synthesis in female species.(3)
Overview
As an agonist analog of GnRH, researchers have suggested that Triptorelin binds to the receptors in the pituitary gland, which may then stimulate the secretion of LH and FSH. This, at first, may cause an upsurge in the initial phase of LH and FSH stimulation. However, it is important to note that Triptorelin is an analog that appears to have upregulated stability and affinity to the receptors than endogenous GnRH. Thus, the receptors eventually may become less sensitive to the compound (i.e., downregulation of the receptors), and Triptorelin may lead to reduced release of LH and FSH.
Scientists consider that a reduction in the levels of LH and FSH hormones eventually leads to a decrease in testosterone and estrogen levels. This event may lead to the suppression of steroidogenesis by ovaries and testicles.(4) Researchers suggest that Triptorelin exhibits some potential in sustaining the decline in LH and FSH secretion. Therefore, intermittent exposure to Triptorelin may upregulate hormonal levels, while prolonged exposure may lead to dramatic suppression.
Chemical Makeup
Molecular Formula: C64H82N18O13
Molecular Weight: 1311.4 g/mol
Other Known Titles: 57773-63-4
Research and Clinical Studies
Triptorelin Peptide and Hormonal Upregulation
It is posited that a single exposure to Triptorelin may, under certain experimental conditions, potentially induce a surge in hormone release from cells by interacting with receptors that control gonadotropin secretion.(5) This single interaction may temporarily reset or stimulate the hypothalamic-pituitary axis, thereby possibly enhancing the secretion of endogenous gonadotropins and subsequent hormonal synthesis. It is hypothesized that Triptorelin might activate signaling pathways that had been previously suppressed or downregulated, possibly leading to an increase in luteinizing hormone release and ultimately fostering the synthesis of androgens. The signaling pathways may be suppressed due to previous exposure to androgenic anabolic agents, which may
“have pronounced effects on the male pituitary-gonadal axis, affecting the regulation of production of serum luteinizing hormone (LH) and follicle-stimulating hormone and inducing a state of hypogonadotropic hypogonadism characterized by decreased serum endogenous testosterone production and impaired spermatogenesis”.
Studies employing controlled conditions have suggested that even a one-time exposure could serve as a catalyst for restoring or augmenting endogenous hormone production. The underlying biological processes, however, remain complex and may depend on multiple variables that have yet to be fully elucidated.
Triptorelin Peptide and Hormonal Suppression
Prolonged exposure to triptorelin may, according to various mechanistic hypotheses, alter the normal function of GnRH receptors.(6) Instead of the typical pulsatile pattern that is possibly required to maintain receptor sensitivity, the continuous presence of a GnRH analog might potentially lead to a state of receptor desensitization. This desensitization, as posited by some researchers, may potentially be tied to alterations in receptor trafficking, where receptors may become internalized and apparently not recycled to the cell surface as efficiently. Such a process may diminish their ability to respond to further stimulation, thereby reducing the secretion of upstream hormones, and ultimately lowering the synthesis of downstream hormones.
Studies employing controlled research approaches have hinted that this continuous stimulation may induce conformational changes in the receptor or associated signaling proteins. These changes may disrupt the receptor’s normal feedback and resensitization mechanisms. Over time, this condition could result in persistently dampened signaling cascades, potentially leading to less hormonal release and reduced hormone production at later stages in the endocrine pathway.
Triptorelin Peptide and Thymus Cells
In murine models, GnRH-analog peptides structurally related to Triptorelin have been posited to interact with specific binding sites within thymic compartments, potentially influencing immune-related processes.(7) It is possible that age-related reductions in LHRH-binding sites, coupled with complex endocrine-immune signaling pathways, obscure the precise manner in which Triptorelin might modulate thymic function. The researchers have commented that the peptide may “exert a powerful modulation of immune system function during the physiological decline of immunological capacities.” However, the limited data currently available may stem from the difficulty in separating local thymic actions from broader neuroendocrine influences, as well as from the challenges of elucidating how these peptides apparently alter receptor densities, cellular organization, and the proliferative capacity of T-lymphocyte precursors. Therefore, it remains uncertain how Triptorelin could potentially modulate immunity at the molecular and cellular level.
Triptorelin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
References:
- National Center for Biotechnology Information. PubChem Compound Summary for CID 25074470, Triptorelin.
- Tsutsumi, Rie, and Nicholas J G Webster. “GnRH pulsatility, the pituitary response and reproductive dysfunction.” Endocrine journal vol. 56,6 (2009): 729-37. doi:10.1507/endocrj.k09e-185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307809/
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Triptorelin. https://www.ncbi.nlm.nih.gov/books/NBK548756/
- Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/
- Pirola I, Cappelli C, Delbarba A, Scalvini T, Agosti B, Assanelli D, Bonetti A, Castellano M. Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism. Fertil Steril. 2010 Nov;94(6):2331.e1-3. doi: 10.1016/j.fertnstert.2010.03.042. Epub 2010 Apr 22. PMID: 20416868.
- Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center. J Korean Med Sci. 2021 Aug 30;36(34):e219. doi: 10.3346/jkms.2021.36.e219. PMID: 34463062; PMCID: PMC8405405.
- Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G Jr, Farinella Z, Cordaro S, Scapagnini U. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology. 1989 Aug;125(2):1037-45. doi: 10.1210/endo-125-2-1037. PMID: 2546733.
Reviews
There are no reviews yet.